Navigation Links
NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
Date:10/31/2007

EMERYVILLE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (Amex, TSX: NBY) today announced the closing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of U.S.$4.00 per share. NovaBay has granted to the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price to cover over-allotments, if any. The shares are trading on the American Stock Exchange and the Toronto Stock Exchange under the symbol "NBY".

Dundee Securities Corporation acted as the sole book runner for the offering, with Desjardins Securities Inc. as co-lead manager. The shares were offered in Canada by an underwriting syndicate co-led by Dundee Securities Corporation and Desjardins Securities Inc. and including Blackmont Capital Inc., and in the United States by Dundee Securities Inc. and Dawson James Securities, Inc.

Copies of the United States prospectus may be obtained from Dawson James Securities, Inc., Attn: Investment Banking, 925 South Federal Highway, 6th Floor, Boca Raton, FL 33432, telephone number (866) 928-0928. Copies of the Canadian prospectus may be obtained from Dundee Securities Corporation, 1 Adelaide St. E., Suite 2700, Toronto, Ontario M4T 1J9; Attn: Equity Capital Markets, E-mail: ecm@dundeesecurities.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, and there shall be no sale of these securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province or jurisdiction.

About NovaBay

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Delinquent boys at increased risk of premature death and disability by middle age 2Health News:Delinquent boys at increased risk of premature death and disability by middle age 3Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2Health News:Urine Sample May Reveal Sleep Disorder in Kids 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:NBTY To Webcast Presentation; Wedbush Securities California Dreamin' Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009 2Health News:NBTY To Webcast Presentation; Wedbush Securities California Dreamin' Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009 3Health News:NBTY To Webcast Presentation; Wedbush Securities California Dreamin' Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009 4
Other Medicine News:Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 3Health News:Artist Neera Dahiya Featured at Silent Auction Held During HealthCorps' Green Garden Gala 2Health News:Artist Neera Dahiya Featured at Silent Auction Held During HealthCorps' Green Garden Gala 3Health News:FertilityTies.com Convention Open to the Public, June 6, 1-5 PM at The Hilton New York Hotel, MDs to Lead Discussion on Timely Fertility Topics 2Health News:Author Mary Soliel Receives Third National Book Award for Debut Non-Fiction on Synchronicity 2Health News:Author Mary Soliel Receives Third National Book Award for Debut Non-Fiction on Synchronicity 3Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 2Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 3Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 4